Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH' Liver Function Trial of RencofilstatGlobeNewsWire • 05/19/23
Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023GlobeNewsWire • 04/17/23
Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLsGlobeNewsWire • 03/30/23
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug DevelopmentGlobeNewsWire • 03/16/23
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH CongressGlobeNewsWire • 03/02/23
EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion's Patent PortfolioGlobeNewsWire • 03/02/23
Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023GlobeNewsWire • 02/09/23
Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma StudiesGlobeNewsWire • 01/18/23
Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome InhibitorsGlobeNewsWire • 01/10/23
Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023GlobeNewsWire • 01/05/23
Hepion Pharmaceuticals, Inc. Granted 180-day Extension by Nasdaq to Meet the Minimum Bid Price RequirementsGlobeNewsWire • 12/05/22
Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH' Liver Function TrialGlobeNewsWire • 12/05/22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred StockGlobeNewsWire • 11/04/22
Hepion Pharmaceuticals Announces Publication of Phase 2a ‘AMBITION' Clinical Trial ResultsGlobeNewsWire • 10/26/22
Hepion Pharmaceuticals Announces Publication of Food Effect Study with RencofilstatGlobeNewsWire • 10/20/22
Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc ConferenceGlobeNewsWire • 09/26/22
Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical's Rencofilstat to Treat Alcohol-Related Liver DiseaseGlobeNewsWire • 09/14/22
Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of StockholdersGlobeNewsWire • 07/22/22
Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar LbiatiGlobeNewsWire • 06/28/22
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of StockholdersGlobeNewsWire • 06/24/22
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular CarcinomaGlobeNewsWire • 06/20/22
Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022GlobeNewsWire • 06/15/22
Hepion Pharmaceuticals Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual MeetingGlobeNewsWire • 05/31/22